Orchid Pharma Ltd., a leading pharmaceutical company headquartered in Chennai, today announced its Quarter 2 financial results for fiscal year 2024-25, demonstrating continued growth in PAT (Profit After Tax) at 26%, highlighting a strong growth trajectory fuelled by expanding sales, operational efficiency, and path breaking product. The reported increase in Q2 2024-25 sales is compared to the same period in the previous year i.e. 2023-24.

Orchid Pharma’s sales reached Rs. 222.7 crores, with EBITDA at Rs. 37.5 crores. Reflecting a solid performance for the first half of FY2025 (H1), the company’s cumulative sales amounted to Rs. 467.1 crores, a notable 22% year-over-year increase compared to H1 FY2024. EBITDA for H1 rose to Rs. 78.6 crores, underscoring the effectiveness of Orchid’s focus on cost control, productivity, and efficiency gains.

Commenting on the results, Manish Dhanuka, Managing Director, Orchid Pharma said: “Our growth is a testament to disciplined operational execution and the momentum from our strategic business development initiatives like the newly launched Orchid AMS. The positive trajectory is proof of our commitment to driving sustainable, profitable growth.”

This quarter, Orchid Pharma achieved key milestones with 7ACA project and the Indian launch of ORBLICEF, its innovative Enmetazobactam-Cefepime drug, marking it as the first Indian discovered drug now commercialized in the EU and approved in the U.S. Backed by a marketing partnership with CIPLA and promising initial results on Indian strains, ORBLICEF is set to make a significant impact on healthcare outcomes. Orchid Pharma also launched the Orchid AMS division, aimed at enhancing its antimicrobial stewardship initiatives, further solidifying its commitment to addressing global health challenges and advancing responsible use of antibiotics. Additionally, the sales of Enmetazobactam have commenced in Europe and Orchid anticipates further growth in the U.S., signaling progress in its global expansion efforts.

“Orchid Pharma also successfully broke ground on its 7ACA project, as planned, on Ganesh Chaturthi, an auspicious day. Despite initial delays due to extended rains, the project is now advancing rapidly, and Orchid is excited to continue driving this significant development forward.

“With strong Q2 results, a promising product pipeline, and strategic investments in capacity and partnerships, Orchid Pharma is well-positioned to capitalize on emerging opportunities. The company’s progress exemplifies its dedication to operational excellence and disciplined execution, creating substantial value for stakeholders and strengthening its standing in the pharmaceutical industry.